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Abstract  
 
 
Background Asthma is commonly treated during pregnancy, yet data on the safety of 
asthma medicines used during pregnancy is sparse.  
Objective To evaluate the safety of the inhaled corticosteroid (ICS) fluticasone 
propionate (FP), alone and in fixed-dose combination with salmeterol (FSC) in terms 
of the risk of all major congenital malformations (MCMs), compared with all other 
non-FP ICS. 
Methods Women with asthma who had a pregnancy between 1-Jan-2000 and 31-
Dec-2010 were identified in the United Kingdom’s Clinical Practice Research 
Datalink. Exposure to asthma medicines during the first trimester of pregnancy was 
based on issued prescriptions. The mother and infants’ medical records were linked 
where possible and pregnancy outcomes with an MCM diagnosed by age 1 year 
were identified based on medical codes in the mother and infant’s medical records, 
including those MCMs prenatally diagnosed that ended in an induced pregnancy 
termination. The absolute and relative risks of an MCM following different ICS 
exposures, stratified by asthma treatment intensity level, were calculated.  
Results 14,654 mother-infant pairs were identified, of which 6,174 received an ICS 
prescription during the first trimester, in addition to 13 first trimester ICS exposed 
pregnancies that ended in an induced termination following a prenatal MCM 
diagnosis. In total, 5,362 pregnancies were eligible for the primary analysis at age 1 
year. The absolute risk of an MCM following any first trimester FP exposure was 
2.4% (CI95 0.8-4.1) and 2.7% (CI95 1.8-3.6) for the ‘moderate’ and 
‘considerable/severe’ asthma treatment intensity levels respectively. The adjusted 
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odds ratios when compared to non-FP ICS were 1.1 (CI95 0.5-2.3) and 1.2 (CI95 0.7-
2.0) for the ‘moderate’ and ‘considerable/severe’ intensity levels; risks for any FP 
and for FSC did not differ substantially. 
Conclusion No increase in the overall risk of MCMs was identified following first 
trimester FP exposure compared with non-FP ICS. 
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Highlights box (35 words max per questions) 
 
 
What is already known about this topic?  (N = 35) 
Little is known about the safety of many inhaled corticosteroids when used during 
pregnancy and with the exception of the Swedish Medical Birth Register study of 
budesonide there is limited data from studies in humans. 
 
What does the article add to our knowledge?  (N = 32) 
This study found no increase in the overall risk of major congenital malformations 
following exposure to fluticasone propionate during the first trimester of pregnancy 
compared with exposure to non-fluticasone propionate inhaled corticosteroids. 
 
How does the study impact current management guidelines?  (N = 29) 
This study supports the findings of studies evaluating the safety of other inhaled 
corticosteroids and provides reassurance to women and clinicians that fluticasone 
propionate is not a major teratogen. 
 
Key words (Max 10) 
pregnancy; asthma; anti-asthmatic agents; congenital abnormalities; electronic 
medical records; teratogens; 
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Abbreviations 
 
BDP  Beclometasone dipropionate 
BTS  British Thoracic Society 
CPRD  Clinical Practice Research Datalink 
FP  Fluticasone propionate 
FSC Fluticasone propionate in fixed dose combination with salmeterol 
(Seretide®) 
GP  General Practitioner 
GPRD  General Practice Research Database 
ICS  Inhaled corticosteroid 
LABA  Long-acting β2-agonist 
LMP  Last menstrual period 
MCM  Major congenital malformations 
No  Number 
SABA  Short-acting β2-agonist
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Introduction  
Asthma affects between 3% and 14% of pregnancies.[1-5] Maternal asthma, and in 
particular poorly controlled asthma, is associated with a number of adverse perinatal 
outcomes including preterm delivery and pre-eclampsia.[6, 7] Consequently, asthma 
treatment guidelines highlight the importance of maintaining good asthma control 
during pregnancy, with inhaled corticosteroids (ICS) recommended as first line 
controller therapies.[8] Pregnant women, however, are typically excluded from 
randomised controlled trials and at present there is little knowledge about the safety 
of many asthma medicines when used during pregnancy. As a result, all ICS with the 
exception of budesonide, which is category B based on data from the Swedish 
Medical Birth Register, have a Food and Drug Administration pregnancy category C, 
indicative of the fact there are no adequate and well controlled studies in humans. 
 
Fluticasone propionate (FP) is an ICS used for the treatment of asthma, as mono-
therapy and in fixed-dose combination with the long-acting β2-agonist (LABA) 
salmeterol. Owing to small numbers of pregnancy exposures in the past, little is 
known about its safety when used during pregnancy. A recent feasibility study,[5] 
however, demonstrated that there are now sufficient numbers of first trimester 
exposed pregnancies in the Clinical Practice Research Datalink (CPRD) to allow the 
overall risk of major congenital malformations (MCMs) to be evaluated. This study 
aimed to evaluate the safety profile of FP, in terms of the risk of MCMs, compared 
with all other non-FP ICS exposures, whilst taking into account potential 
confounders.  
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Methods 
The CPRD, previously the General Practice Research Database, contains anonymised 
patient medical and prescribing records from UK primary care.[9] Within the CPRD it 
is possible to link a mother’s medical record to her infant’s, enabling the evaluation 
of data on both maternal drug exposure and pregnancy outcomes.[10-12] Data is 
entered as Read clinical codes and general practitioners (GPs) can record additional 
non-coded free text comments, which researchers can request from the database 
provider. This protocol was approved by the CPRD Independent Scientific Advisory 
Committee and there is a single Multi-Centre Ethics approval for observational 
studies using CPRD data. 
 
Women with a pregnancy starting and ending between 01-Jan-2000 and 31-Dec-
2010 were identified, who were aged 11-50 years at the start of pregnancy. 
Pregnancies were identified using algorithms previously developed and utilised at 
the University of Bath.[5, 13] The pregnancy start date was estimated based on 
medical codes in the woman’s record; where information was not available a 
defaulted pregnancy duration of 40 weeks for live- and stillbirths and 10 weeks for 
pregnancy losses was used. The defaulted duration was used for approximately 40% 
of deliveries and 70% of pregnancy losses. Women were required to have had a 
singleton birth and have been followed in the CPRD for the six months before, 
throughout and for at least three months following pregnancy. A more detailed 
description of the methods has been described previously.[5] 
 
Women were considered to have asthma if they had:  
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(a) an asthma diagnosis at any time in their medical record and ≥2 prescriptions 
for any asthma medicine during the study period or 
(b) ≥6 prescriptions for any asthma medicine during the study period  
 
Asthma medicines included short-acting β2-agonists (SABA), ICS, LABA, compound 
bronchodilator preparations, cromoglicate and related therapy, leukotriene receptor 
antagonists, antimuscarinic bronchodilators and theophylline products and did not 
include the use of intranasal steroids. Women were required to receive ≥1 
prescription during the six months before or during pregnancy. Women with a 
diagnosis of any other chronic respiratory disease were excluded.  
 
For all asthma medicines the duration of each prescription was calculated.[5] In 
addition to those described above, oral corticosteroid prescriptions were identified 
where there was no evidence they had been prescribed for a condition other than 
asthma. Each prescription was given a start and end date and the prescriptions were 
mapped, taking into account the switching of products.[5] Periods of long-term oral 
corticosteroid use (≥90 days) were included in the mapping whilst short courses (<90 
days) were used to identify acute asthma exacerbations. The mapped prescription 
data was then used to determine the combination of products a patient was exposed 
to during each day of the study period.[5]  
 
Women were assigned to treatment steps based on the combination of products 
prescribed and The British Thoracic Society and Scottish Intercollegiate Guidelines on 
the management of asthma.[8] Women were only allocated to a Step 5 if long term 
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oral corticosteroid use was combined with a current prescription for high dose ICS 
(>800μg for beclomethasone dipropionate (BDP) or budesonide and >400μg for FP). 
 
Each treatment step was assigned a value and an average treatment step value was 
calculated for each woman for the entire pregnancy, for each trimester and for the 
three months before pregnancy as shown below. 
 
Σ (number of days on each treatment step x step value) 
total number of days in time period 
 
Individuals were categorised into one of three ‘asthma treatment intensity levels’ 
based on their average British Thoracic Society and Scottish Intercollegiate 
Guidelines treatment step value during each particular time period (‘mild’: ≤Step 1; 
‘moderate’: >Step 1 and ≤Step 2; ‘considerable to severe’: >Step 2). The category 
‘considerable to severe’ included a wide range, with 51.2% classified as >Step 2 and 
≤Step 3, 47.9% classified as >Step 3 and ≤ Step 4 and the remainder being > Step 4 
and ≤Step 5. 
 
First trimester ICS exposure was defined as the issue of a prescription for any ICS 
during the first trimester or the 2 weeks preceding. FP exposure was categorised into 
‘FP alone’ (Flixotide®), ‘FP in fixed-dose combination with salmeterol’ (Seretide® 
(FSC)) and ‘any FP’. Women who received both ‘FP alone’ and ‘FSC’ were eligible for 
inclusion in both groups but only counted once in the ‘any FP’ category. Women 
were included in the non-FP ICS category if they received a non-FP ICS prescription 
and no prescriptions for an FP product, regardless of the prescribing of any other 
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asthma medicine classes. All exposure was determined masked to pregnancy 
outcome status. 
 
For live deliveries the mother’s medical record, where possible, was linked to that of 
the infant; this was possible for approximately 80% of deliveries. MCMs were 
identified based on a Read code relating to an MCM in the infant’s record. Major 
congenital malformations (MCMs) were defined according to the EUROCAT 
classification.[14, 15] In infants diagnosed with a syndrome, syndrome-related MCMs 
were excluded as these were unlikely to be drug induced but any MCMs that were 
not reported in the literature as being part of that syndrome were included. Each 
potential MCM was verified using either supporting medical codes in the infant’s 
record (e.g. surgery code), free text comments or by sending a questionnaire to the 
infant’s GP. MCMs were identified in pregnancies that ended in a stillbirth or 
induced termination by requesting and reviewing free text comments recorded in 
association with a pregnancy related medical code in the mother’s record.  
 
Analyses 
The maternal patient characteristics were reported for all pregnancies where the 
woman received a prescription for an ICS, stratified by type of ICS. For pregnancies 
where the mother’s medical record could be linked to that of the child or the 
pregnancy had ended in a pregnancy termination, the absolute risk of a pregnancy 
outcome with an MCM diagnosed by 1 year of age was calculated as shown below 
for each ICS exposure group, stratified by first trimester asthma treatment intensity 
level. Stillbirths and pregnancy losses without an MCM were excluded from the 
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denominator because of the likelihood of inconsistent identification of defects 
across these types of outcome; this approach is commonly taken by pregnancy 
registries.[16] To be eligible for the analyses at one year of age infants had to still be 
registered in the CPRD at, or had died before, the time of their first birthday. 
No of live deliveries with MCM + no of stillbirths with MCM + no of pregnancy losses with MCM 
Total no of live deliveries + no of stillbirths with MCM + no of pregnancy losses with MCM 
 
The relative risk of a pregnancy outcome with an MCM, diagnosed by 1 year of age, 
following first trimester exposure to FP compared to all non-FP ICS was calculated, 
stratified by first trimester asthma treatment intensity level. Multivariate logistic 
regression was used to adjust for maternal age, alcohol consumption, smoking 
status, socioeconomic status, body-mass-index, change in asthma treatment step, 
oral corticosteroid use and exacerbation occurrence. This was carried out separately 
for FP alone and FSC and also for the ‘any FP’ category as there was no 
heterogeneity between exposure groups.  
 
The primary outcome was an MCM diagnosed by one year of age because previous 
research had demonstrated that approximately only two-thirds of MCMs were 
recorded in an infant’s medical record by 3 months of age. Sensitivity analyses were, 
however, carried out to evaluate the risks of an MCM diagnosed by 3 months of age 
and by 5 years of age in order to assess any impact on the risk estimates of loss to 
follow-up and to look at the impact of any malformations diagnosed later in life. 
Further sensitivity analyses were carried out by excluding MCMs where it was not 
possible to confirm or refute the diagnosis following the verification exercise. All 
12 
Charlton 
 
 12 
analyses were carried out using Stata version 12.[17] To investigate the impact of non-
independent pregnancies, where one woman contributed more than one pregnancy 
to the study cohort, sensitivity analyses were carried out for the primary outcome of 
interest (an MCM diagnosed by 1 year of age), restricting the analyses to the first 
pregnancy of each woman.  
 
The prevalence of MCM organ classes, identified in the different FP exposure groups, 
were calculated and compared to those reported by the UK contributing EUROCAT 
registries.[18]  
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Results 
In total, 25,247 pregnancies in 18,674 women with asthma were identified, of which 
18,120 (71.8%) ended in a delivery. An ICS prescription had been issued during the 
first trimester in 10,770 pregnancies. Of these, 3,311 (30.7%) had received a 
prescription for FP; 807 for FP alone and 2,558 for FSC (Figure 1a). Non-FP ICS use 
consisted of beclomethasone dipropionate (~80%), budesonide in a single inhaler 
(~10%) and budesonide in a fixed-dose combination with the LABA formoterol 
(~10%). The demographic patient characteristics of women prescribed FP during the 
first trimester were comparable with those prescribed a non-FP ICS (Table 1). In 
general, women prescribed FSC did not differ from those prescribed FP alone on 
demographic features, although FSC users were more likely to be smokers (p<0.01). 
With respect to differences in asthma, women receiving FP were more likely to be at 
the more severe end of the asthma treatment severity strata than women 
prescribed a non-FP ICS (Table 1). Women prescribed FP were also more likely to 
have experienced an asthma exacerbation in the six months before pregnancy 
(p<0.01) and to have received an oral corticosteroid prescription during the first 
trimester (p<0.01) than those prescribed a non-FP ICS. 
 
Within the asthma cohort 14,654 mother-infant pairs were identified, of which 6,174 
were exposed to an ICS during the first trimester and 5912, 5362 and 2062 
pregnancies were eligible for the primary and sensitivity analyses at 3 months, 1 year 
and 5 years of age respectively (Figure 1b). A total of 622 potential MCMs in 514 
pregnancies were identified (including 43 chromosomal defects and 35 syndrome 
related). Figure 2 shows the results of the verification exercise.  
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Of the 5,362 ICS exposed pregnancies eligible for the primary analysis at 1 year of 
age, 131 pregnancies were identified with an unrefuted MCM diagnosed by aged 1 
year (including MCMs where it was not possible to verify or refute the diagnosis and 
excluding chromosomal defects and defects part of a syndrome). There was no 
evidence of an increase in MCM risk for the offspring of women who received a 
prescription for FP during the first trimester compared to women who received a 
non-FP ICS product (Table 2). In addition, no substantial differences were observed 
in those prescribed FP alone compared to those prescribed FSC. Restricting the 
analysis to only verified MCMs did not substantially change the risk estimates 
(Online repository Table E1).  
 
No meaningful differences were observed when sensitivity analyses restricted MCMs 
to those diagnosed by 3 months of age (Table E2).  When the analyses were 
restricted to MCMs diagnosed by 5 years, the absolute risks for FP exposed women 
were slightly higher than those prescribed a non-FP ICS. The differences observed, 
however, were not statistically significant and the number of exposures in some 
groups was low (Table E2). Restricting the primary analyses to the first pregnancy of 
each woman reduced the point estimates below the null for those with moderate 
asthma treatment intensity but did not substantially change the confidence intervals 
or the overall study findings (Table E3). 
 
For all MCM subgroups, with the exception of the ‘urinary subgroup’ in the non-FP 
ICS exposed group where the prevalence was higher, comparison of the prevalences 
in the CPRD with data from UK contributing EUROCAT registries, restricted to the 
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same study period, did not demonstrate any evidence of an increase in risk following 
ICS exposure (Table E4).  
 
Discussion 
 
This study did not identify any increase in the overall risk of MCMs following 
exposure to FP during the first trimester of pregnancy compared with exposure to 
non-FP ICS. In addition, the risk of MCMs following first trimester exposure to FP 
alone was not found to differ to the risk following exposure to FSC. To our 
knowledge, this is one of the first large population-based studies to evaluate the 
safety of FP when used during pregnancy in relation to the risk of MCMs and also to 
specifically evaluate the safety of an ICS delivered as part of a fixed-dose 
combination product with a LABA. 
 
This study included over 25,000 pregnant women with asthma, including over 10,000 
who received an ICS prescription during the first trimester. The prevalence of asthma 
and the frequency of asthma medicine prescribing in the GPRD has been 
demonstrated to be similar to that described elsewhere,[5] implying that the cohort is 
reasonably representative of the wider pregnant population with asthma. 
 
Data on asthma medicines were recorded prospectively and independently by the 
prescriber, preventing maternal recall bias. Exposure was, however, based on the 
issue of a prescription and it was not possible to know whether it was dispensed and 
used, or used as directed with proper inhaler technique. The nature of asthma and 
the high levels of poor treatment compliance will have resulted in some non-
16 
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differential exposure misclassification and this would likely have resulted in a bias 
towards the null. Inclusion of prescriptions issued during the two weeks before the 
start of pregnancy will have helped to identify some, but not all, women who were 
exposed during the early stages of pregnancy but did not receive a prescription 
during the pregnancy itself. Misclassification of exposure may also have resulted 
from limitations in estimating the start of pregnancy and subsequently the precise 
timing of exposure. The lack of patient reported information (e.g. Asthma Control 
Test) in electronic medical databases is a limitation. Although this study attempted 
to take into account treatment intensity, the level of symptom control provided by a 
particular treatment regimen will vary between women. Within the CPRD, data on 
changes in symptom control that may not have been associated with a change in 
treatment regimen or required intervention with oral steroids were not available. No 
information was also available on medicines bought without a prescription, including 
400mcg folic acid which is known to reduce the risk of some MCMs when taken 
during the peri-conception period.[19, 20]  
 
This study identified a wide range of MCMs and had the strength of capturing 
prenatally diagnosed MCMs resulting in an induced termination. It is possible some 
MCMs may not have been recorded in a patient’s record but this is unlikely to be 
differential between exposure groups. This study, like the budesonide study,[21] did 
however evaluate the risk of all MCMs combined, and it is recognised that this is 
usually insufficiently sensitive for detecting specific teratogenic associations. 
Although this study attempted to control for effects of varying ‘asthma severity’ this 
measure was based on asthma treatment patterns and did not take into account 
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treatment compliance or additional clinical asthma symptoms that are not routinely 
recorded in the CPRD. It is possible this will have resulted in some confounding by 
indication which may not have been fully adjusted for in the stratified analyses and 
multivariate modelling.  
 
This study compared FP exposure with exposure to all other non-FP ICS, and 
therefore one limitation is that if a class effect of an increased risk of MCMs 
associated with ICS exposure exists, then this study design would not have been able 
to identify such a class-effect. Given that treatment step guidelines recommend ICS 
as the backbone of persistent asthma maintenance therapy beginning in Step 2, in an 
observational study design it is not feasible to study a class-effect without potential 
confounding by severity. 
 
A small number of studies have reported on first trimester ICS exposure and the risk 
of congenital malformations.[21-28]  Many of these, however, have grouped all ICS 
products and have been limited by small numbers. Based on the studies available, 
there is general consensus that the use of ICS products during early pregnancy does 
not appear to be associated with an increased risk of congenital malformations 
overall when compared to either users of non-ICS asthma medicines[23, 25] or the 
general population.[21, 22] The findings of our study are in line with the published 
data. A recent study by Eltonsy et al., compared the use of long-acting β2-agonists 
and inhaled corticosteroids in combination with higher-dose inhaled corticosteroid 
monotherapy and found the risk of MCMs was similar for the two groups.[29] 
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Neither our study nor the Swedish study looked at ICS dose and its relationship with 
MCM risk. A study using Canadian electronic healthcare data[24] has suggested that 
higher ICS dose  (>1,000μg/d BDP equivalent) may be associated with an increased 
risk of congenital malformations when compared to low/moderate doses 
(≤1,000μg/d). The adjusted odds ratios were 1.66 (CI951.02-2.68) and 1.67 (CI950.91-
3.06) for all congenital malformations and MCMs respectively, when high-dose ICS 
was compared to low/moderate doses. No increase in risk was observed when 
low/moderate exposures were compared to no ICS. The number of high-dose 
exposures was, however, small (N=154) and it was not possible to rule out 
confounding by disease severity as a possible explanation for the observed increased 
risk. 
 
Conclusion 
In our population-based cohort study, FP users were at the more severe end of the 
asthma severity spectrum and therefore would be less likely to successfully 
discontinue their asthma medicines during pregnancy without the increased risk of 
asthma exacerbations and other symptoms. Our study found no evidence of an 
increased risk of MCMs following exposure to FP during the first trimester of 
pregnancy when compared to non-FP ICS. This is reassuring and in line with other 
studies evaluating the safety of ICS products. This study had 90% power to detect a 
two-fold increase in the risk of all MCMs diagnosed by one year of age but was not 
powered to detect smaller increases in risk. In addition to providing information on 
the safety profile of FP and other ICS, this study also in part evaluated the safety of 
the LABA salmeterol used in a fixed-dose combination with FP. Whilst FP exposures 
19 
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were mostly in combination with salmeterol in this study (77.9%) and the 
preliminary findings were reassuring,  further data on the safety of LABA-containing 
regimens used during pregnancy are required to increase the precision of the risk 
estimates and further inform prescribers and patient decision making aiming to 
optimize asthma control during pregnancy.[30]  
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Table 1 Patient characteristics of women exposed to fluticasone propionate (FP) or 
another inhaled corticosteroid during the first trimester of pregnancy 
 
 
Patient characteristic 
Non-FP inhaled 
corticosteroids 
FP alone 
(Flixotide®) 
FSC (Seretide®) Any FP product 
  N            (%) N (%) N (%) N (%) 
Number of pregnancy outcomes 7,459  807  2,558  3,311  
Mean age at LMP (years [SD]) 29.4  [6.6]  29.9  [6.3]  29.7  [6.4]  29.7  [6.4]  
Age at LMP (years)         
 <20 669 (9.0) 42 (5.2) 178 (7.0) 217 (6.6) 
 20-24 1,160 (15.6) 121 (15.0) 411 (16.1) 521 (15.7) 
 25-29 1,779 (23.9) 210 (26.0) 631 (24.7) 834 (25.2) 
 30-34 2,071 (27.8) 245 (30.4) 725 (28.3) 952 (28.8) 
 35-39 1,369 (18.4) 138 (17.1) 470 (18.4) 600 (18.1) 
 40+ 411 (5.5) 51 (6.3) 143 (5.6) 187 (5.7) 
Smoking status              
 non-smoker 3,589 (48.1) 436 (54.0) 1,199 (46.9) 1,606 (48.5) 
 current smoker 2,390 (32.0) 211 (26.2) 801 (31.3) 997 (30.1) 
 ex-smoker 1,469 (19.7) 159 (19.7) 556 (21.7) 705 (21.3) 
 unknown 11 (0.2) 1 (0.1) 2 (0.1) 3 (0.1) 
Alcohol drinking status             
 teetotal 1,020 (13.7) 127 (15.7) 362 (14.2) 480 (14.5) 
 drinks alcohol 4,969 (66.6) 548 (67.9) 1,716 (67.1) 2,229 (67.3) 
 heavy drinker 129 (1.7) 10 (1.2) 44 (1.7) 54 (1.6) 
 ex-drinker 352 (4.7) 24 (3.0) 124 (4.9) 145 (4.4) 
 unknown 989 (13.3) 98 (12.1) 312 (12.2) 403 (12.2) 
Body mass index (before LMP)              
 <20 797 (10.7) 82 (10.2) 258 (10.1) 337 (10.2) 
 20 - 24 2,680 (35.9) 280 (34.7) 933 (36.5) 1,189 (35.9) 
 25 - 29 1,656 (22.2) 198 (24.5) 600 (23.5) 789 (23.8) 
 30 - 34 823 (11.0) 89 (11.0) 286 (11.2) 366 (11.1) 
 >34 519 (7.0) 39 (4.8) 230 (9.0) 264 (8.0) 
 Unknown 984 (13.2) 119 (14.8) 251 (9.8) 366 (11.1) 
Socioeconomic status (practice level)             
 quintile 1 – least deprived 1,257 (16.9) 152 (18.8) 480 (18.8) 624 (18.9) 
 quintile 2 1,399 (18.8) 199 (24.7) 436 (17.0) 621 (18.8) 
 quintile 3 1,539 (19.4) 122 (15.1) 481 (18.8) 593 (17.9) 
 quintile 4 1,595 (21.4) 146 (18.1) 489 (19.1) 628 (19.0) 
 quintile 5 – most deprived 1,759 (23.6) 188 (23.3) 672 (26.3) 845 (25.5) 
Pregnancy history1         
No of Previous deliveries     0 3,504 (47.0) 401 (49.7) 1,146 (44.8) 1,518 (45.8) 
 1 2,484 (33.3) 287 (35.6) 881 (34.4) 1,152 (34.8) 
 2 1,027 (13.8) 92 (11.4) 376 (14.7) 461 (13.9) 
 >2 444 (6.0) 27 (3.3) 155 (6.1) 180 (5.4) 
Previous pre-term delivery  283 (3.8) 19 (2.4) 94 (3.7) 112 (3.4) 
Previous spontaneous loss  1,203 (16.1) 125 (15.5) 466 (18.2) 585 (17.7) 
                                                 
1 Recorded in the GPRD 
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Table 1 continued  
 
 
Patient characteristic 
Non-FP inhaled 
corticosteroids 
               N          (%) 
FP alone 
(Flixotide®) 
            N          (%) 
FSC (Seretide®) 
 
           N          (%) 
Any FP product 
 
            N          (%) 
Asthma treatment intensity level         
 Mild 162 (2.2) 10 (1.2) 12 (0.5) 22 (0.7) 
 Moderate 5,139 (68.9) 274 (34.0) 350 (13.7) 623 (18.8) 
 Considerable to severe 2,158 (28.9) 523 (64.8) 2,196 (85.8) 2,666 (80.5) 
Change in average BTS treatment 
step2 
        
 >1.0 decrease 141 (1.9) 41 (5.1) 145 (5.7) 186 (5.6) 
 >0.5 and ≤1.0 decrease 217 (2.9) 32 (4.0) 118 (4.6) 146 (4.4) 
 Remained the same 4,967 (66.6) 514 (63.7) 1,568 (61.3) 2,050 (61.9) 
 >0.5 and ≤1.0 increase 1,489 (20.0) 98 (12.1) 232 (9.1) 322 (9.7) 
 >1.0 increase 645 (8.6) 122 (15.1) 495 (19.4) 607 (18.3) 
Asthma exacerbation in 6 months 
before pregnancy 
        
 Yes 754 (10.1) 155 (19.2) 505 (19.7) 638 (19.3) 
 No 6,705 (89.9) 652 (80.8) 2,053 (80.3) 2,673 (80.7) 
Prescription for an oral corticosteroid 
during the first trimester* 
        
 Yes 385 (5.2) 78 (9.7) 230 (9.0) 299 (9.0) 
 No 7,074 (94.8) 729 (90.3) 2,328 (91.0) 3,012 (91.0) 
* either as part of a Step 5 treatment regimen or issued for less than a 90 day duration in relation to 
the treatment of an exacerbation. 
 
 
                                                 
2 Between the 3 month period before pregnancy and the first trimester 
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Table 2 Risk of a pregnancy outcome with a major congenital malformation (MCM) 
diagnosed by 1 year of age for first trimester FP exposed pregnancies compared to 
all other non-FP ICS exposed pregnancies, stratified by first trimester asthma 
treatment intensity level 
 
Asthma treatment intensity 
level and first trimester 
exposure type 
No of exposed 
pregnancies* 
             N           (%)** 
No of pregnancies 
with an MCM† 
          
Absolute risk of 
an MCM (95% CI) 
Adjusted odds 
ratio± (95% CI) 
Mild 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
72 
7 
3 
10 
 
(1.2) 
(0.1) 
(0.0) 
(0.2) 
 
4 
0 
0 
0 
 
5.6  (0.3 – 10.8) 
0.0 
0.0 
0.0 
 
Moderate 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
2,598 
152 
177 
328 
 
(64.1) 
(3.8) 
(4.4) 
(8.1) 
 
60 
3 
5 
8 
 
2.3  (1.7 – 2.9) 
2.0  (0.0 – 4.2) 
2.8  (0.4 – 5.3) 
2.4  (0.8 – 4.1) 
 
1 
0.9  (0.3 – 2.9) 
1.3  (0.5 – 3.2) 
1.1  (0.5 – 2.3) 
Considerable to severe 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
1,080 
273 
1,032 
1,274 
 
(43.0) 
(10.9) 
(41.1) 
(50.7) 
 
25 
8 
27 
34 
 
2.3  (1.4 – 3.2)   
2.9  (0.9 – 4.9) 
2.6  (1.6 – 3.6) 
2.7  (1.8 – 3.6) 
 
1 
1.3  (0.6 – 3.0) 
1.1  (0.6 – 2.0) 
1.2  (0.7 – 2.0) 
*  Ending in either a delivery or an induced termination of pregnancy following a prenatal MCM 
diagnosis 
** Percentage treated with this category of ICS within this asthma treatment intensity level 
†   Including MCMs where it was not possible to verify or refute the diagnosis 
±   Adjusted for maternal age, socioeconomic status and maternal smoking status 
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Figure legends 
 
Figure 1 Flow diagram of the asthma study cohort showing a breakdown of 
pregnancy outcome status and inhaled corticosteroid prescribing 
 
Figure 2 Flow diagram of the asthma study cohort showing the identification of 
pregnancies eligible for the congenital malformation analyses 
 
Figure 3 Verification of potential major congenital malformations 
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18,120 deliveries 
10,770 received an inhaled 
corticosteroid prescription during 
the 1st trimester 
3,311 received a fluticasone 
propionate (FP) prescription 
during the 1st trimester 
807* for FP not part of a 
fixed-dose combination 
25,247 pregnancies  
in 18,674 women with asthma 
2,558* for FP as part of a 
fixed-dose combination  
7,127 pregnancy losses 
5,362 eligible for 
MCM primary 
analyses at 1 year 
of age 
* 54 women received a prescription for FP both as part of a fixed-dose combination and as an inhaler not part of a fixed-dose combination during the 
1st trimester  
Figure 1.  
   MCM = major congenital malformation 
 
Figure 2.  
14,654 for which it was possible to link the 
mother’s medical record to the medical record 
of the child 
6,174 received an inhaled corticosteroid (ICS) 
prescription during the 1st trimester 
+  
13 terminations of pregnancy following a non-
chromosomal and non-syndrome prenatal MCM 
diagnosis who had received an ICS 
2,062 eligible for 
MCM sensitivity 
analyses at 5 
years of age 
5,912 eligible for 
MCM sensitivity 
analyses at 3 
months of age 
18,120 deliveries 
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Figure 3 
  
535 (86.0%) 
Confirmed 
622 potential MCMs 
65 (10.5%) 
Unable to confirm or 
refute 
22 (3.5%) 
Refuted 
542 in live births 
12 in stillbirths 
46 in terminations of pregnancy 
506 (84.3%) 
Still registered at 1 year of age or 
died before reaching 1 year 
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Repository E tables 
 
Table EI Risk of a pregnancy outcome with a major congenital malformation (MCM) 
diagnosed by 1 year of age for first trimester FP exposed pregnancies compared to 
all other non-FP ICS exposed pregnancies stratified by first trimester asthma 
treatment intensity level restricted to MCMs that could be verified. 
 
Asthma treatment intensity 
level and first trimester 
exposure type 
No of exposed 
pregnancies* 
             N           (%)** 
No of pregnancies 
with an MCM 
          
Absolute risk of 
an MCM (95% CI) 
Adjusted odds 
ratio± (95% CI) 
Mild 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
72 
7 
3 
10 
 
(1.2) 
(0.1) 
(0.0) 
(0.2) 
 
4 
0 
0 
0 
 
5.6  (0.3 – 10.8) 
0.0 
0.0 
0.0 
 
 
Moderate 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
2,598 
152 
177 
328 
 
(64.1) 
(3.8) 
(4.4) 
(8.1) 
 
56 
3 
5 
8 
 
2.2  (1.6 – 2.7) 
2.0  (0.0 – 4.2) 
2.8  (0.4 – 5.3) 
2.4  (0.8 – 4.1) 
 
1 
0.9  (0.3 – 2.9) 
1.3  (0.5 – 3.2) 
1.1  (0.5 – 2.4) 
Considerable to severe 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
1,080 
273 
1,032 
1,274 
 
(43.0) 
(10.9) 
(41.1) 
(50.7) 
 
22 
7 
26 
32 
 
2.0  (1.2 – 2.9) 
2.6  (0.7 – 4.4) 
2.5  (1.6 – 3.5) 
2.5  (1.7 – 3.4) 
 
1 
1.5  (0.6 – 3.4) 
1.2  (0.7 – 2.2) 
1.2  (0.7 – 2.1) 
* ending in either a delivery or an induced termination of pregnancy following a prenatal MCM 
diagnosis 
** percentage treated with this category of ICS within this asthma treatment intensity level 
±   Adjusted for maternal age, socioeconomic status and maternal smoking status 
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Table EII Risk of a pregnancy outcome with a major congenital malformation (MCM) 
for first trimester FP exposed pregnancies compared to all other non-FP ICS exposed 
pregnancies, stratified by first trimester asthma treatment intensity level 
 
a) diagnosed by 3 months of age 
 
Asthma treatment intensity 
level and first trimester 
exposure type 
No of exposed 
pregnancies* 
             N           (%)** 
No of pregnancies 
with an MCM† 
          
Absolute risk of 
an MCM (95% CI) 
Adjusted odds 
ratio± (95% CI) 
Mild 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
82 
7 
3 
10 
 
(1.2) 
(0.1) 
(0.0) 
(0.1) 
 
3 
0 
0 
0 
 
3.7  (0.00 – 7.7)   
0.0 
0.0 
0.0 
 
 
Moderate 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
2,868 
159 
203 
361 
 
(64.0) 
(3.6) 
(4.5) 
(8.1) 
 
47 
3 
5 
8 
 
1.6  (1.2 – 2.1) 
1.9  (0.0 – 4.0) 
2.5  (0.3 – 4.6) 
2.2  (0.7 – 3.7) 
 
1 
1.2  (0.4 – 3.9) 
1.6  (0.6 – 4.0) 
1.4  (0.7 – 3.0) 
Considerable to severe 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
1,169 
283 
1,171 
1,422 
 
(42.2) 
(10.2) 
(42.2) 
(51.2) 
 
18 
2 
24 
25 
 
1.5  (0.8 – 2.2) 
0.7  (0.0 – 1.7) 
2.1  (1.2 – 3.0) 
1.8  (1.1 – 2.4) 
 
1 
0.5  (0.1 – 2.1) 
1.3  (0.7 – 2.5) 
1.1  (0.6 – 2.1) 
 
b) diagnosed by 5 years of age 
 
Asthma treatment intensity 
level and first trimester 
exposure type 
No of exposed 
pregnancies* 
             N           (%)** 
No of pregnancies 
with an MCM† 
          
Absolute risk of 
an MCM (95% CI) 
Adjusted odds 
ratio± (95% CI) 
Mild 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
24 
4 
0 
4 
 
(1.1) 
(0.2) 
(0.0) 
(0.2) 
 
0 
0 
0 
0 
 
0.0 
0.0 
0.0 
0.0 
 
Moderate 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
1,080 
66 
51 
117 
 
(67.1) 
(4.1) 
(3.2) 
(7.3) 
 
39 
3 
1 
4 
 
3.6  (2.5 – 4.7)   
4.6  (0.0 – 9.6)   
2.0  (0.0 – 5.8)   
3.4  (0.1 – 6.7)   
 
1 
1.3  (0.4 – 4.4) 
0.5  (0.1 – 3.9) 
0.9  (0.3 – 2.7) 
Considerable to severe 
Non-FP ICS 
FP alone (Flixotide®) 
FSC (Seretide®) 
Any FP exposure 
 
446 
155 
248 
391 
 
(49.4) 
(17.2) 
(27.5) 
(43.3) 
 
14 
8 
12 
19 
 
3.1  (1.5 – 4.8) 
5.2  (1.7 – 8.6) 
4.8  (2.2 – 7.5) 
4.9  (2.7 – 7.0) 
 
1 
1.7  (0.7 – 4.3) 
1.6  (0.7 – 3.5) 
1.6  (0.8 – 3.3) 
*  Ending in either a delivery or an induced termination of pregnancy following a prenatal MCM 
diagnosis 
** Percentage treated with this category of ICS within this asthma treatment intensity level 
†   Including MCMs where it was not possible to verify or refute the diagnosis 
±   Adjusted for maternal age, socioeconomic status and maternal smoking status 
 
 
30 
Charlton 
 
 30 
Table EIII Prevalence of major congenital malformations diagnosed by 1 year of age 
stratified by first trimester ICS exposure and grouped according to the EUROCAT 
criteria 
 
(  ) = additional MCMs where it was not possible to confirm or refute the diagnosis 
   * = observed to be higher than the prevalence reported by EUROCAT and 95% confidence intervals 
for the two data sources did not overlap.  
 
Major congenital malformation 
Non-FP inhaled 
corticosteroid 
N = 3,750 
FP alone 
(Flixotide®) 
N = 432 
FSC 
(Seretide®) 
N = 1,212 
                N¥     (%)† N¥ (%)† N¥     (%)† 
Nervous system 6 0.16 (0.03-0.29) ≤5 ≤1.16 (0.15-2.17) ≤5 ≤0.41 (0.05-0.77) 
Eye ≤5 ≤0.13 (0.02-0.25) 0  0  
Ear, face and neck  0  0  0  
Congenital heart defects  (3) 27 0.72 (0.45-0.99) ≤5 ≤1.16 (0.15-2.17) 13 1.07 (0.49-1.65) 
Respiratory   0  0  0  
Oro-facial clefts  ≤5 ≤0.13 (0.02-0.25) 0  ≤5 ≤0.41 (0.05-0.77) 
Digestive system  (1)  7 0.21 (0.07-0.36) ≤5 ≤1.16 (0.15-2.17) ≤5 ≤0.41 (0.05-0.77) 
Abdominal wall defects ≤5 ≤0.13 (0.02-0.25) 0   0  
Urinary  (2) 20 0.59 (0.34-0.83)* 0  6 0.50 (0.10-0.89) 
Genital  6 0.16 (0.03-0.29) ≤5 ≤1.16 (0.15-2.17) ≤5 ≤0.41 (0.05-0.77) 
Limb  (2) 18 0.53 (0.30-0.77) ≤5 ≤1.16 (0.15-2.17) 6 0.50 (0.10-0.89) 
Other anomalies / syndromes (2)  4 0.16 (0.03-0.29) (≤5) ≤1.16 (0.15-2.17) (≤5)   ≤5 <0.41 (0.05-0.77) 
Teratogenic syndromes with 
malformations   ≤5 ≤0.13 (0.02-0.25) 0  (≤5) <0.41 (0.05-0.77) 
MCM type unknown – pregnancy 
ended in an induced termination ≤5 ≤0.13 (0.02-0.25) 0  ≤5 <0.41 (0.05-0.77) 
†  Includes MCMs where it was not possible to confirm or refute the diagnosis 
¥ Reported as N ≤5 to ensure patient anonymity  
 
 
 
